RU2017141446A - ENANTIOMERS OF 2-HYDROXY DERIVATIVE FATTY ACIDS - Google Patents

ENANTIOMERS OF 2-HYDROXY DERIVATIVE FATTY ACIDS Download PDF

Info

Publication number
RU2017141446A
RU2017141446A RU2017141446A RU2017141446A RU2017141446A RU 2017141446 A RU2017141446 A RU 2017141446A RU 2017141446 A RU2017141446 A RU 2017141446A RU 2017141446 A RU2017141446 A RU 2017141446A RU 2017141446 A RU2017141446 A RU 2017141446A
Authority
RU
Russia
Prior art keywords
cancer
enantiomer
pharmaceutically acceptable
formula
pathology
Prior art date
Application number
RU2017141446A
Other languages
Russian (ru)
Other versions
RU2017141446A3 (en
RU2687967C2 (en
Inventor
Пабло Висенте ЭСКРИБА РУИС
Мария Лаура МАРТИН
Мария Антония НОГЕРА САЛЬВА
Ксавьер БУСКЕТС КСАУБЕТ
Давид ЛОПЕС ХИМЕНЕС
Майтане ИБАРГУРЕН АЙСПИТАРТЕ
Хосе Хавьер СОТО САЛЬВАДОР
Мигель ИУС АСТИС
Original Assignee
Университат Де Лес Ильес Балеарс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Университат Де Лес Ильес Балеарс filed Critical Университат Де Лес Ильес Балеарс
Publication of RU2017141446A publication Critical patent/RU2017141446A/en
Publication of RU2017141446A3 publication Critical patent/RU2017141446A3/ru
Application granted granted Critical
Publication of RU2687967C2 publication Critical patent/RU2687967C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
    • C07C51/493—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification whereby carboxylic acid esters are formed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (16)

1. Энантиомер [-] формулы1. Enantiomer [-] of the formula [-]НООС-НОСН-(СН2)6-(СН=СН-СН2)2-(СН2)3-CH3 или его фармацевтически приемлемые соли.[-] HOOC-HOCH- (CH 2 ) 6 - (CH = CH-CH 2 ) 2 - (CH 2 ) 3 -CH 3 or a pharmaceutically acceptable salt thereof. 2. Энантиомер по п. 1, отличающийся тем, что указанный энантиомер представляет собой фармацевтически приемлемую соль формулы2. The enantiomer according to claim 1, characterized in that said enantiomer is a pharmaceutically acceptable salt of the formula [-]NaOOC-НОСН-(СН2)6-(СН=СН-СН2)2-(СН2)3-СН3.[-] NaOOC-HCH - (CH 2 ) 6 - (CH = CH-CH 2 ) 2 - (CH 2 ) 3 -CH 3 . 3. Фармацевтическая композиция для лечения патологии, вызванной аномально низким уровнем сфингомиелина и/или аномально низким уровнем глиофибриллярного кислого белка (ГФКБ) и/или аномально высоким уровнем дигидрофолатредуктазы (ДГФР), содержащая терапевтически эффективное количество энантиомера формулы3. A pharmaceutical composition for treating a pathology caused by an abnormally low level of sphingomyelin and / or an abnormally low level of gliofibrillar acid protein (GFKB) and / or an abnormally high level of dihydrofolate reductase (DHFR), containing a therapeutically effective amount of an enantiomer of the formula [-]НООС-НОСН-(СН2)6-(СН=СН-СН2)2-(СН2)3-CH3 и/или по меньшей мере одной из его фармацевтически приемлемых солей и, необязательно, фармацевтически приемлемый носитель.[-] NOOS-NOSH- (CH 2 ) 6 - (CH = CH-CH 2 ) 2 - (CH 2 ) 3 -CH 3 and / or at least one of its pharmaceutically acceptable salts and, optionally, a pharmaceutically acceptable carrier . 4. Фармацевтическая композиция по п. 3, отличающаяся тем, что указанный энантиомер представляет собой фармацевтически приемлемую соль формулы4. The pharmaceutical composition according to claim 3, characterized in that said enantiomer is a pharmaceutically acceptable salt of the formula [-]NaOOC-НОСН-(СН2)6-(СН=СН-СН2)2-(СН2)3-CH3.[-] NaOOC-LOCCH- (CH 2 ) 6 - (CH = CH-CH 2 ) 2 - (CH 2 ) 3 -CH 3 . 5. Способ лечения патологий, общая этиология которых представляет собой аномально низкий уровень сфингомиелина и/или аномально низкий уровень глиофибриллярного кислого белка (ГФКБ) и/или аномально высокий уровень дигидрофолатредуктазы (ДГФР), включающий введение пациенту терапевтически эффективного количества энантиомера формулы5. A method of treating pathologies whose overall etiology is an abnormally low level of sphingomyelin and / or an abnormally low level of gliofibrillar acid protein (GFKB) and / or an abnormally high level of dihydrofolate reductase (DHFR), comprising administering to the patient a therapeutically effective amount of an enantiomer of the formula [-]НООС-НОСН-(СН2)6-(СН=СН-СН2)2-(СН2)3-СН3 и/или по меньшей мере одной из его фармацевтически приемлемых солей или композиции, содержащей указанный энантиомер и/или по меньшей мере одну из его фармацевтически приемлемых солей.[-] NOOS-NOSH- (CH 2 ) 6 - (CH = CH-CH 2 ) 2 - (CH 2 ) 3 -CH 3 and / or at least one of its pharmaceutically acceptable salts or compositions containing the specified enantiomer and / or at least one of its pharmaceutically acceptable salts. 6. Способ по п. 5, отличающийся тем, что указанный энантиомер представляет собой фармацевтически приемлемую соль формулы6. The method according to p. 5, characterized in that the enantiomer is a pharmaceutically acceptable salt of the formula [-]NaOOC-HOCH-(CH2)6-(CH=CH-CH2)2-(CH2)3-CH3.[-] NaOOC-HOCH- (CH 2 ) 6 - (CH = CH-CH 2 ) 2 - (CH 2 ) 3 -CH 3 . 7. Способ по п. 5, отличающийся тем, что указанная патология, в отношении которой проводят лечение, выбрана из группы, состоящей из рака, сосудистых патологий и метаболических патологий.7. The method according to p. 5, characterized in that the pathology for which treatment is carried out is selected from the group consisting of cancer, vascular pathologies and metabolic pathologies. 8. Способ по п. 7, отличающийся тем, что указанный рак выбран из рака печени, меланомы, рака предстательной железы, рака молочной железы, рака поджелудочной железы, лейкоза, рака шейки матки, рака толстой кишки, рака мозга или рака легких.8. The method according to p. 7, characterized in that said cancer is selected from liver cancer, melanoma, prostate cancer, breast cancer, pancreatic cancer, leukemia, cervical cancer, colon cancer, brain cancer or lung cancer. 9. Способ по п. 7, отличающийся тем, что указанная сосудистая патология выбрана из гипертонии, атеросклероза, кардиомиопатий, ангиогенеза, гиперплазии сердца.9. The method according to p. 7, characterized in that said vascular pathology is selected from hypertension, atherosclerosis, cardiomyopathy, angiogenesis, cardiac hyperplasia. 10. Способ по п. 7, отличающийся тем, что указанная метаболическая патология выбрана из диабета, метаболического синдрома или ожирения.10. The method according to p. 7, characterized in that said metabolic pathology is selected from diabetes, metabolic syndrome or obesity.
RU2017141446A 2011-10-07 2012-10-08 Enantiomers of 2-hydroxy derivatives of fatty acids RU2687967C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES201131622 2011-10-07
ES201131622A ES2401629B1 (en) 2011-10-07 2011-10-07 ENANTIOMERS OF 2-HYDROXIDERIVATES OF FATTY ACIDS AND THEIR USE AS MEDICINES.
US201261610762P 2012-03-14 2012-03-14
US61/610,762 2012-03-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014118123A Division RU2637937C2 (en) 2011-10-07 2012-10-08 Enantiomers-2-hydroxy-derivatives of fatty acids

Publications (3)

Publication Number Publication Date
RU2017141446A true RU2017141446A (en) 2019-02-13
RU2017141446A3 RU2017141446A3 (en) 2019-02-13
RU2687967C2 RU2687967C2 (en) 2019-05-17

Family

ID=48043212

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017141446A RU2687967C2 (en) 2011-10-07 2012-10-08 Enantiomers of 2-hydroxy derivatives of fatty acids
RU2014118123A RU2637937C2 (en) 2011-10-07 2012-10-08 Enantiomers-2-hydroxy-derivatives of fatty acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014118123A RU2637937C2 (en) 2011-10-07 2012-10-08 Enantiomers-2-hydroxy-derivatives of fatty acids

Country Status (12)

Country Link
US (1) US9359281B2 (en)
EP (2) EP3287437B1 (en)
JP (1) JP2014530806A (en)
CN (1) CN104321300A (en)
DK (1) DK2774910T3 (en)
ES (3) ES2401629B1 (en)
HU (1) HUE035430T2 (en)
IN (1) IN2014CN03111A (en)
PL (1) PL2774910T3 (en)
PT (1) PT2774910T (en)
RU (2) RU2687967C2 (en)
WO (1) WO2013050644A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (en) * 2009-03-16 2011-09-08 Lipopharma Therapeutics USE OF 2-HYDROXIDERIVATES OF POLYINSATURATED FATTY ACIDS AS MEDICINES.
RU2679443C2 (en) 2014-10-21 2019-02-11 Университат Де Лес Ильес Балеарс Method for synthesis of hydroxy-triglycerides and uses thereof for prevention and treatment of diseases
EP4234035A3 (en) * 2017-05-16 2023-11-15 Ability Pharmaceuticals S.A. A pharmaceutical combination for the treatment of a cancer
WO2019099664A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
ES2846824B2 (en) * 2020-01-29 2022-01-19 Univ Illes Balears PRODRUGS OF POLYUNSATURATED FATTY ACIDS AND THEIR MEDICAL USES
JP2023518640A (en) * 2020-01-29 2023-05-08 ウニバシタット デ レス イレス バレアース Alpha-hydroxylated fatty acid metabolites, their medical uses and their use as biomarkers
ES2911474B2 (en) * 2020-11-17 2023-02-06 Univ Illes Balears PRODRUGS OF MONOUNSATURATED FATTY ACIDS AND THEIR METABOLITES: MEDICAL USES AND AS BIOMARKERS
MX2022008623A (en) * 2020-02-10 2022-08-08 Ability Pharmaceuticals S L A pharmaceutical combination for the treatment of a cancer.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2235541C2 (en) * 1994-10-04 2004-09-10 Эмори Юниверсити Treatment of atherosclerosis and other cardio-vascular diseases
AUPR547601A0 (en) * 2001-06-05 2001-06-28 Carcraft Qld Pty Ltd Tab with writing surface
ES2186576B1 (en) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears 2-HYDROXYOLEIC ACID TO USE AS A MEDICINAL PRODUCT.
ES2342997B1 (en) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears ALPHA DERIVATIVES OF CIS-MONOINSATURATED FATTY ACIDS TO BE USED AS A MEDICINAL PRODUCT.
ES2345241B1 (en) * 2009-03-16 2011-09-08 Lipopharma Therapeutics USE OF 2-HYDROXIDERIVATES OF POLYINSATURATED FATTY ACIDS AS MEDICINES.

Also Published As

Publication number Publication date
CN104321300A (en) 2015-01-28
EP3287437B1 (en) 2019-12-11
DK2774910T3 (en) 2018-01-08
RU2017141446A3 (en) 2019-02-13
IN2014CN03111A (en) 2015-07-03
ES2773784T3 (en) 2020-07-14
EP3287437A1 (en) 2018-02-28
EP2774910A1 (en) 2014-09-10
PL2774910T3 (en) 2018-03-30
WO2013050644A1 (en) 2013-04-11
RU2014118123A (en) 2015-11-20
HUE035430T2 (en) 2018-05-02
ES2401629B1 (en) 2014-03-04
US9359281B2 (en) 2016-06-07
JP2014530806A (en) 2014-11-20
US20140288176A1 (en) 2014-09-25
EP2774910B1 (en) 2017-09-27
RU2637937C2 (en) 2017-12-08
PT2774910T (en) 2018-01-03
EP2774910A4 (en) 2015-02-25
ES2653675T3 (en) 2018-02-08
RU2687967C2 (en) 2019-05-17
ES2401629A1 (en) 2013-04-23

Similar Documents

Publication Publication Date Title
RU2017141446A (en) ENANTIOMERS OF 2-HYDROXY DERIVATIVE FATTY ACIDS
RU2477723C2 (en) Protein kinase inhibitor (versions), use thereof for treating oncological diseases and based pharmaceutical composition
CN103945848B (en) The oral immediate release formulations of the quinazolinone being replaced
JP6595078B2 (en) Aminocarbonyl carbamate compounds
RU2012112050A (en) DERIVATIVES OF DIHYDROPERTERIDINONE, METHOD FOR PRODUCING THERE AND PHARMACEUTICAL USE
JP2013518050A5 (en)
RU2014113679A (en) N- (2-AMINO-6,6-DIFTOR-4,4A, 5,6,7,7A-HEXAHYDRO-CYCLOPENTA [E] [1,3] OXAZIN-4-IL) -PHENYL) -AMIDS AS INHIBITORS BETA SECRETASES 1
EA201001159A1 (en) Condensed Heterocyclic Derivatives and Their Application
RU2015100901A (en) Heteroaryl Carboxylic Acid Derivatives
RU2017121460A (en) Derivatives of pyridinecarboxamide, a method for their production and their pharmaceutical use
EA200601350A1 (en) NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATIONS
JP2018519340A (en) Use of chloroquine and clemizole compounds to treat inflammatory and cancerous conditions
RU2011124894A (en) C-MET TRIAZOLOTHYADIAZOL INHIBITOR
JP2016538281A5 (en)
JP2008530242A5 (en)
RU2013122898A (en) Pohoxime conjugates applicable for the treatment of pathologies associated with the HSP90, composition and method of treatment using them
EA201390659A1 (en) METHODS OF TREATMENT WITH THE APPLICATION OF LIPID COMPOUNDS
CN106795114A (en) Novel iminonitrile derivative
JP2017533964A5 (en)
RU2012135698A (en) METHOD AND COMPOSITION
CA2933907A1 (en) Selective hdac6 inhibitors
JP2015502371A5 (en)
JP2016523830A (en) Radiation mitigation pharmaceutical formulation
JP2016523830A5 (en)
EP2772481A8 (en) Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof